Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Johnson & Johnson : Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:58pm CEST

Reports on Pharmaceutical Research Findings from Johnson & Johnson Provide New Insights (Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Pharmaceutical Research. According to news reporting originating from Beerse, Belgium, by NewsRx correspondents, research stated, "The present study investigated the influence of in vitro dissolution conditions on the in vivo predictability of an amorphous solid dispersion of celecoxib (CCX) in the pH-sensitive polymer Eudragit ® S 100. Different doses of a 25:75 w/w% CCX: Eudragit ® S 100 amorphous solid dispersion (CCX:EUD) were investigated."

Our news editors obtained a quote from the research from Johnson & Johnson, "During in vitro dissolution a significant effect of the pH of the dissolution media on the release of CCX was observed. In fasted state simulated intestinal fluid (FaSSIF) pH 6.5, the release of CCX from the amorphous solid dispersion was comparable to that of crystalline CCX and lower than that of amorphous CCX whereas in FaSSIF pH 7.4, the release was significantly increased compared to both crystalline and amorphous CCX. With a 3-fold increase in the exposure of CCX: EUD compared to crystaline CCX. The in vivo data also suggested that Eudragit ® S 100 was suitable as a carrier in amorphous solid dispersions of CCX. In vitro-in vivo correlation demonstrated that the in vitro data obtained in FaSSIF pH 7.4 was more predictive for the in vivo performance than that obtained in FaSSIF pH 6.5."

According to the news editors, the research concluded: "Consequently, the findings of this study underline that when predicting the in vivo performance of amorphous solid dispersions with pH-sensitive polymers, it is imperative that the in vitro dissolution conditions are carefully considered."

For more information on this research see: Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier. International Journal of Pharmaceutics, 2017;531(1):324-331. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.journals.elsevier.com/international-journal-of-pharmaceutics/)

The news editors report that additional information may be obtained by contacting R. Holm, Johnson & Johnson, Drug Prod Dev, Janssen Res & Dev, BE-2340 Beerse, Belgium. Additional authors for this research include M.M. Knopp, F. Khan, N. Chourak, T. Rades and J. Wendelboe (see also Drugs and Therapies - Pharmaceutical Research).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ijpharm.2017.08.078. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Beerse, Belgium, Europe, Pharmaceutical Research, Drugs and Therapies, Johnson & Johnson.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
09/20JOHNSON & JOHNSON : Health-Related Quality of Life Maintained with Addition of E..
AQ
09/20MCKESSON : Board of Directors Elects Dominic Caruso as New Independent Director
AQ
09/20JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
AQ
09/20JOHNSON & JOHNSON : Janssen Submits New Drug Application to FDA Seeking Approval..
AQ
09/20MAILMYLENS.COM OFFERING THE BEST OF : Mailmylens.com is providing a variety of ..
AQ
09/19JOHNSON & JOHNSON : to Host Investor Conference Call on Third-Quarter Results
PR
09/19JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. FDA Seeking App..
PU
09/19PFIZER : Drug companies cheating countries out of billions in tax revenues, reve..
AQ
09/18JOHNSON & JOHNSON : Expert panel holds first meeting to decide compensation for ..
AQ
09/18PFIZER : Drug Companies Cheating Countries Out of Billions in Tax Revenues
AQ
More news
News from SeekingAlpha
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/19My Quarterly Global Portfolio Update 
09/19Surviving The Geron Roller Coaster As An Investor 
09/18J&J files U.S. marketing application for erdafitinib for urothelial cancer 
Financials ($)
Sales 2018 81 257 M
EBIT 2018 24 952 M
Net income 2018 16 036 M
Debt 2018 11 280 M
Yield 2018 2,52%
P/E ratio 2018 20,96
P/E ratio 2019 18,13
EV / Sales 2018 4,83x
EV / Sales 2019 4,59x
Capitalization 381 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 144 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.53%380 898
PFIZER19.44%253 595
NOVARTIS-0.56%216 184
ROCHE HOLDING LTD.-4.65%211 637
MERCK AND COMPANY25.79%186 114
AMGEN17.99%131 526